Financial Comparison
Baxter International Inc. vs Johnson & Johnson
Click a ticker to view the full analysis.
BAX vs
In short
Johnson & Johnson is the more profitable of the two, keeping 28.5% of revenue as net profit against -8.5% for Baxter International Inc. Fisclear flags 2 medium- or high-severity risks for Baxter International Inc. and 1 for Johnson & Johnson.
Based on filings for periods ending 30 Jun 2026 (BAX) and 27 Sept 2026 (JNJ) · Updated
FisclearScore Comparison
BAX46Weak
JNJ64Fair
Quality+24
54
78
Efficiency+20
30
50
Value+16
36
52
Cashflow+15
62
77
Regime
55
55
Peers+26
42
68
FisclearScore is a quantitative model. BAX shown solid · JNJ shown dashed. Not financial advice.
| Metric | BAX | JNJ |
|---|---|---|
| Price | $23.90 | $257.78 |
| Market Cap | $12.4B | $621.2B |
| P/E (TTM) | — | 39.1x |
| P/B | 2.0x | 7.3x |
| Beta | 0.65 | 0.21 |
| Div Yield | 0.16% | 2.07% |
| Revenue (TTM) | $11.2B | $94.2B |
| Net Income | -$957M | $26.8B |
| Gross Margin | 30.1% | 67.9% |
| Risk Flags | 2 flags | 1 flag |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.